Jonathan S. Zager, MD

Articles by Jonathan S. Zager, MD

Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases

September 27th 2022

Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive Melanoma

ByAmod A. Sarnaik, MD,Jonathan S. Zager, MD,Vernon K. Sondak, MD

October 15th 2016

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.

Latest Updated Articles

POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive Melanoma
Published: October 15th 2016 | Updated:
Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases
Published: September 27th 2022 | Updated:

Jonathan S. Zager, MD

Articles by Jonathan S. Zager, MD

Jonathan S. Zager, MD, on Results of Phase 3 FOCUS Trial Examining Percutaneous Hepatic Perfusion in Ocular Melanoma With Hepatic Metastases

POINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive Melanoma

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC